Free Trial
NASDAQ:PACB

Pacific Biosciences of California Q1 2025 Earnings Report

Pacific Biosciences of California logo
$1.10 -0.03 (-2.21%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pacific Biosciences of California EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

Pacific Biosciences of California Revenue Results

Actual Revenue
N/A
Expected Revenue
$36.90 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pacific Biosciences of California Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Pacific Biosciences of California Earnings Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Cathie Wood’s ARK Investment bought 143.5K shares of PacBio today
Bernstein Keeps Their Buy Rating on Pacific Biosciences (PACB)
See More Pacific Biosciences of California Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacific Biosciences of California? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacific Biosciences of California and other key companies, straight to your email.

About Pacific Biosciences of California

Pacific Biosciences of California (NASDAQ:PACB) designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

View Pacific Biosciences of California Profile

More Earnings Resources from MarketBeat